Check out this guest post by Alan D. D’Andrea, MD, and Elizabeth M. Swisher, MD from the
SU2C-OCRF-OCNA-NOCC Dream Team that originally appeared on Cancer Research Catalyst, the official blog of the American Association for Cancer Research, the Scientific Partner of Stand Up 2 Cancer.
September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease.
This year we are pleased to have seen some encouraging signs. At the Annual Meeting of the American Association for Cancer Research (AACR) in April, scientists reported that a combination of two drugs, olaparib and BKM120, showed clinical benefit for women with high-grade serous ovarian cancer (as well as women with triple-negative breast cancer). Click plus sign to read on…